{"id":183795,"date":"2023-07-26T00:00:00","date_gmt":"2023-07-25T22:00:00","guid":{"rendered":"https:\/\/www.bcfi.be\/le-point-sur-le-daclizumab-zinbryta-5-ans-apres-sa-commercialisation-4\/"},"modified":"2023-07-26T00:00:00","modified_gmt":"2023-07-25T22:00:00","slug":"le-point-sur-le-daclizumab-zinbryta-5-ans-apres-sa-commercialisation-4","status":"publish","type":"post","link":"https:\/\/cbip.be\/fr\/le-point-sur-le-daclizumab-zinbryta-5-ans-apres-sa-commercialisation-4\/","title":{"rendered":"Le point sur le daclizumab (Zinbryta\u00ae), 5 ans apr\u00e8s sa commercialisation"},"content":{"rendered":"<div class=&quot;summary&quot;>Il y a 5 ans&#x002C; le daclizumab (Zinbryta\u00ae) \u00e9tait commercialis\u00e9 avec comme indication le traitement des formes r\u00e9currentes-r\u00e9mittentes de scl\u00e9rose en plaques. En 2018&#x002C; cet antagoniste du r\u00e9cepteur de l&#39;IL-2 a \u00e9t\u00e9 retir\u00e9 du march\u00e9 par la firme apr\u00e8s que l&#39;Agence europ\u00e9enne des m\u00e9dicaments ait lanc\u00e9 une <a href=&quot;https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-immediate-suspension-recall-multiple-sclerosis-medicine-zinbryta&quot;>\u00e9valuation urgente<\/a> en raison du risque d&#39;enc\u00e9phalite et de m\u00e9ningo-enc\u00e9phalite.<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Il y a 5 ans&#x002C; le daclizumab (Zinbryta\u00ae) \u00e9tait commercialis\u00e9  [&#8230;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,14914],"tags":[20213],"class_list":["post-183795","post","type-post","status-publish","format-standard","hentry","category-actualites","category-2023-fr","tag-import_tags"],"_links":{"self":[{"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/posts\/183795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/comments?post=183795"}],"version-history":[{"count":0,"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/posts\/183795\/revisions"}],"wp:attachment":[{"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/media?parent=183795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/categories?post=183795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/tags?post=183795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}